The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
The side effects of platinum-based chemotherapy drugs: a review for chemists
Abstract
The platinum chemotherapy drugs cisplatin, carboplatin, and oxaliplatin are known to cause seven different types of side effects in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Mechanisms of Cisplatin Nephrotoxicity
Miller, R. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2010) · Toxins · doi:10.3390/toxins2112490 · Cited by 1,622
Dhar, S., Liu, Z., Thomale, J., Dai, H., & Lippard, S. J. (2008) · Journal of the American Chemical Society · doi:10.1021/ja803036e · Cited by 700
Zhou, J., Yu, G., & Huang, F. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00898d · Cited by 677
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., Danso, M. A., Dennis, K., Dupuis, L. L., Dusetzina, S. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.4789 · Cited by 628
Cisplatin resistance and opportunities for precision medicine
Amable, L. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.001 · Cited by 589
Cisplatin: a review of toxicities and therapeutic applications
Barabas, K., Milner, R., Lurie, D., & Adin, C. (2008) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2007.00142.x · Cited by 446
Nanocarriers for delivery of platinum anticancer drugs
Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.014 · Cited by 396
Cisplatin Ototoxicity and Protection: Clinical and Experimental Studies
Rybak, L. P., Mukherjea, D., Jajoo, S., & Ramkumar, V. (2009) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.219.177 · Cited by 372
Launay‐Vacher, V., Rey, J., Bagnis, C. I., Deray, G., & Daouphars, M. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0711-0 · Cited by 282
Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies
El-Awady, E.-S. E., Moustafa, Y. M., Abo-Elmatty, D. M., & Radwan, A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.085 · Cited by 260
The state-of-play and future of platinum drugs
Apps, M. G., Choi, E. H. Y., & Wheate, N. J. (2015) · Endocrine-Related Cancer · doi:10.1530/erc-15-0237 · Cited by 256
Self-citationCisplatin Overdose: Toxicities and Management
Tsang, R. Y., Al-Fayea, T., & Au, H.-J. (2009) · Drug Safety · doi:10.2165/11316640-000000000-00000 · Cited by 235
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy
Park, S. B., Lin, C. S.-Y., Krishnan, A. V., Goldstein, D., Friedlander, M. L., & Kiernan, M. C. (2009) · Brain · doi:10.1093/brain/awp219 · Cited by 231
Oldenburg, J., Kraggerud, S. M., Cvancarova, M., Lothe, R. A., & Fossa, S. D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9599 · Cited by 197
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Crawford, J., Becker, P. S., Armitage, J. O., Blayney, D. W., Chávez, J. C., Curtin, P. T., Dinner, S. N., Fynan, T., Gojo, I., Griffiths, E. A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0175 · Cited by 180
Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy
KWEEKEL, D., GELDERBLOM, H., & GUCHELAAR, H. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.12.006 · Cited by 179
Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2
Sprowl, J. A., Ciarimboli, G., Lancaster, C. S., Giovinazzo, H., Gibson, A. A., Du, G., Janke, L. J., Cavaletti, G., Shields, A. F., & Sparreboom, A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305321110 · Cited by 175
Relationship Between Cisplatin Administration and the Development of Ototoxicity
Rademaker-Lakhai, J. M., Crul, M., Zuur, L., Baas, P., Beijnen, J. H., Simis, Y. J. W., van Zandwijk, N., & Schellens, J. H. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.077 · Cited by 174
Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases
Chun, Y. S., Laurent, A., Maru, D., & Vauthey, J.-N. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70064-6 · Cited by 173
Caronia, D., Patiño‐García, A., Milne, R. L., Zalacaín, M., Pita, G., Alonso, M. R., Moreno, L. T., Sierrasesúmaga-Ariznabarreta, L., Benitez, J. J., & González‐Neira, A. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.19 · Cited by 144
Cisplatin binding to human serum albumin: a structural study
Ferraro, G., Massai, L., Luigi Messori, A., & Merlino, A. (2015) · Chemical Communications · doi:10.1039/c5cc01751c · Cited by 136
Jodrell, D. I., Evans, T. R. J., Steward, W. P., Cameron, D., Prendiville, J., Aschele, C., Noberasco, C., Lind, M., Carmichael, J., Dobbs, N. A., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.04.032 · Cited by 130
Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin
Riedemann, L., Lanvers, C., Deuster, D., Peters, U., Boos, J., Jürgens, H., & Zehnhoff‐Dinnesen, A. A. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500455 · Cited by 119
Oxaliplatin: a review of approved uses
Stein, A., & Arnold, D. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.643870 · Cited by 107
Cardiotoxicity: Cisplatin and long-term cancer survivors
Patanè, S. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.04.238 · Cited by 102
Involvement of cytochrome P450 in cisplatin treatment: implications for toxicity
Quintanilha, J. C. F., de Sousa, V. M., Visacri, M. B., Amaral, L. S., Santos, R. M. M., Zambrano, T., Salazar, L. A., & Moriel, P. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3358-x · Cited by 95
Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells
Kalayda, G. V., Wagner, C. H., & Jaehde, U. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.07.010 · Cited by 90
Chemotherapy-Associated Hepatotoxicity: Do We Need to Be Concerned?
Choti, M. A. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0512-7 · Cited by 87
Cisplatin hepatotoxicity mediated by mitochondrial stress
Waseem, M., Bhardwaj, M., Tabassum, H., Raisuddin, S., & Parvez, S. (2015) · Drug and Chemical Toxicology · doi:10.3109/01480545.2014.992437 · Cited by 78
Cisplatin induced arrhythmia; electrolyte imbalance or disturbance of the SA node?
Oun, R., & Rowan, E. G. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.063 · Cited by 64
Self-citationYaogawa, S., Ogawa, Y., Morita-Tokuhiro, S., Tsuzuki, A., Akima, R., Itoh, K., Morio, K., Yasunami, H., Onogawa, M., Kariya, S., et al. (2015) · Cancers · doi:10.3390/cancers8010001 · Cited by 48
Song, K. I., Park, J. T., Lee, S., Lee, D., Jang, H.-J., Kim, S., Ko, H., Kim, H. J., Lee, J. Y., Hwang, G. S., et al. (2015) · Planta Medica · doi:10.1055/s-0035-1545696 · Cited by 46
Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer
Laskey, R. A., Poniewierski, M. S., Lopez, M. A., Hanna, R. K., Secord, A. A., Gehrig, P. A., Lyman, G. H., & Havrilesky, L. J. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.03.015 · Cited by 42
Infliximab Modulates Cisplatin-Induced Hepatotoxicity in Rats
Cüre, M. C., Cüre, E., Kalkan, Y., Kırbaş, A., Tümkaya, L., Yılmaz, A., Türkyılmaz, A. K., Şehitoğlu, İ., & Yuce, S. (2016) · Balkan Medical Journal · doi:10.5152/balkanmedj.2016.150576 · Cited by 32
Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals
Liang, Z. D., Long, Y., Chen, H. H. W., Savaraj, N., & Kuo, M. T. (2013) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-013-1051-z · Cited by 26
Risk?benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting
Herrstedt, J. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.3.231 · Cited by 25
Waalboer, D. C. J., Muns, J. A., Sijbrandi, N. J., Schasfoort, R. B. M., Haselberg, R., Somsen, G. W., Houthoff, H., & van Dongen, G. A. M. S. (2015) · ChemMedChem · doi:10.1002/cmdc.201402496 · Cited by 22
Kagiava, A., Theophilidis, G., Sargiannidou, I., Kyriacou, K. C., & Kleopa, K. A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.05.021 · Cited by 21
Estève, E., Bazin, D. C., Jouanneau, C., Rouzière, S., Bataille, A., Kellum, A., Provost, K., Mocuta, C., Réguer, S., Thiaudière, D., et al. (2016) · Comptes Rendus Chimie · doi:10.1016/j.crci.2016.03.014 · Cited by 19
Aptamers in Targeted Nanotherapy
Mathew, A., Maekawa, T., & Kumar, D. S. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150413153525 · Cited by 14
Cancer cachexia: Are we ready to take a step forward?
Crawford, J. (2017) · Cancer · doi:10.1002/cncr.31126 · Cited by 9
Cited by
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Translational Applications of Hydrogels
Correa, S., Grosskopf, A. K., Lopez Hernandez, H., Chan, D., Yu, A. C., Stapleton, L. M., & Appel, E. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01177 · Cited by 1,143
The rediscovery of platinum-based cancer therapy
Rottenberg, S., Disler, C., & Perego, P. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00308-y · Cited by 972
Nanoparticle Surface Functionalization: How to Improve Biocompatibility and Cellular Internalization
Sanità, G., Carrese, B., & Lamberti, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.587012 · Cited by 765
Bacterial Biofilm Eradication Agents: A Current Review
Verderosa, A. D., Totsika, M., & Fairfull-Smith, K. E. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00824 · Cited by 555
Metadata
- Authors
- Oun, R., Moussa, Y. E., & Wheate, N. J.
- Venue
- Dalton Transactions
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2018
- Volume
- 47
- Issue
- 19
- Pages
- 6645-6653
- ISSN
- 1477-9226 (ISSN-L)
- 1477-9234
- OpenAlex
- W2795139701
- Cited by
- 1,737
- References
- 43
- FWCI
- 48.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.